This message contains images. If you don't see images, click here to view.
Advertise in this news brief.




Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit           May 14, 2014

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store

 

Current guidelines underestimate US cervical cancer incidence and older women's risk
NBC News
Women over age 65, who may believe they no longer need gynecological exams, may be at a much higher risk of cervical cancer than previously believed, researchers reported on Monday. Current guidelines are based on data that don’t take into account the high rate of hysterectomy in the U.S., the team at the University of Maryland School of Medicine found.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE  




Evolving Views of Ovarian Tumor Risk Assessment
FREE CME Activity

Presented by Frederick R. Ueland, M.D., at SGO’s 2014 Annual Meeting, this online, case-based activity provided by Omnia Education focuses on the current use of imaging and ovarian cancer biomarkers in pre-surgical evaluation to assess risk for a malignant ovarian mass. This presentation aims to provide a more complete understanding of best practices leading to more appropriate triage and improved patient outcomes. Read more.

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Advertisement
PRODUCT SHOWCASE
  ChemoFx Improves Ovarian Cancer Outcomes
ChemoFx® provides invaluable information to physicians choosing from 20+ equivalent treatment recommendations without prior knowledge of how individual patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.
 


HPV


New Cervarix two-dose data demonstrate potential for increased flexibility of vaccine administration schedule
Pharmaceutical Business Review
The Phase III clinical trial data from the ongoing HPV 070 study shows that immunogenicity of two doses of Cervarix given at months 0 and 12 is non-inferior to vaccination given at 0 and 6 months, the currently licensed schedule. This research demonstrates the potential for increased flexibility in timing of the administration of the second dose between month 5 and month 13, and may offer healthcare providers a more convenient once yearly vaccination option to help protect more girls against cervical cancer.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


OVARIAN CANCER


Ovarian cancer cells are more aggressive on soft tissues
Science Daily
When ovarian cancer spreads from the ovaries it almost always does so to a layer of fatty tissue that lines the gut. A new study has found that ovarian cancer cells are more aggressive on these soft tissues due to the mechanical properties of this environment. The finding is contrary to what is seen with other malignant cancer cells that seem to prefer stiffer tissues.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


  FEATURED COMPANIES
Exceptional Care, Close to Home

21st Century Oncology – the nation’s largest cancer treatment network and global leader in cancer care – providing integrated clinical teams treating patients collaboratively to improve outcomes.
MORE
Lantheus Proven Success
Discovering, developing and marketing innovative medical imaging agents provides a strong platform from which to bring forward new breakthrough tools for the diagnosis and management of disease. MORE


GENETICS


Few women at high-risk for hereditary breast and ovarian cancer receive genetic counseling
Medical Xpress
Mutations in the BRCA1 and BRCA2 genes account for nearly 25 percent of hereditary breast cancers and most hereditary ovarian cancers, yet a study by cancer prevention and control researchers at Virginia Commonwealth University Massey Cancer Center suggests an alarmingly small amount of women who qualify for BRCA genetic counseling actually receive the services. Additionally, they found that a significant proportion of women with a family history of breast and ovarian cancer underestimate their own risk.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


CERVICAL CANCER


Radiation therapy for cervical cancer increases risk for colorectal cancer
Oncology Nurse Advisor
Young women treated with radiation for cervical cancer should begin colorectal cancer screening earlier than traditionally recommended, according to new research. The researchers, from the University of Texas Medical Branch at Galveston, found a high incidence of secondary colorectal cancers among cervical cancer survivors treated with radiation. So, they have offered new recommendations that the younger women in this group begin colorectal cancer screening about 8 years after their initial cervical cancer diagnosis instead of waiting until age 50 years. The study was published in Medical Oncology.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




MORCELLATION


Morcellation has role in patient care, societies say
Medscape (Free login required)
Recent months have witnessed the eruption of a controversy about the safety of laparoscopic power morcellation, a surgical technique that mechanically fragments tissue to facilitate removal. Now, 2 groups — the American College of Obstetricians and Gynecologists (ACOG) and the European Society of Gynecologic Endoscopy (ESGE) — have weighed in, issuing statements saying morcellation still has a place in gynecologic surgery.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


BREAST CANCER


ASCO issues guidelines for advanced HER-2—positive breast cancer
Healio — HemOnc Today
ASCO recently issued two clinical practice guidelines on treating women with advanced, HER-2–positive breast cancer, published online in the Journal of Clinical Oncology. The first guideline reviews the appropriate systemic therapies for patients with newly-diagnosed with advanced disease and those whose early-stage disease progressed to advanced cancer. The second guideline offers recommendations for treating brain metastases in patients with HER-2–positive advanced breast cancer.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE
 



Women's Cancer News
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Jessica Taylor, Senior Medical Editor, 202-684-7169  
Contribute news


Inclusion of advertisements does not constitute SGO endorsement of company products or services.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

May 7, 2014
April 30, 2014
April 23, 2014
April 16, 2014






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063